CO6160228A2 - Inhibidores de caspasa basados en la estructura de piridazinona - Google Patents
Inhibidores de caspasa basados en la estructura de piridazinonaInfo
- Publication number
- CO6160228A2 CO6160228A2 CO09009364A CO09009364A CO6160228A2 CO 6160228 A2 CO6160228 A2 CO 6160228A2 CO 09009364 A CO09009364 A CO 09009364A CO 09009364 A CO09009364 A CO 09009364A CO 6160228 A2 CO6160228 A2 CO 6160228A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- substituted
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
caracterizado porque I) R1 representa H, alquilo de C1-C5, cicloalquilo de C3-C10, arilo o un residuo de cadena lateral de todos los aminoácidos naturales, II) R2 representa H, alquilo de C1-C5, cicloalquilo de C3-C10, arilo o un residuo de cadena lateral de todos los aminoácidos naturales, III) R3 representa H, alquilo de C1-C5, hidroxi, alcoxi de C1-C5 o halógeno, IV) R4 representa H, alquilo de C1-C5, cicloalquilo de C3-C10 o arilo, V) R5 representa H, alquilo de C1-C5, cicloalquilo de C3-C10 o arilo, VI) R6 y R7 independientemente entre sí cada uno representa H, alquilo de C1-C5, cicloalquilo de C3-C10 o arilo, VII) X representa -CH2OR9 (R9 es alquilo de C1-C5, cicloalquilo de C3-C10 o arilo), -CH2OC(=O)R10 (R10 es alquilo de C1-C5, cicloalquilo de C3-C10 o arilo); -CH2-OP(=O)R112(R11 es alquilo de C1-C5, cicloalquilo de C3-C10 o arilo), o -CH2-W (W es halógeno) o sal farmacéuticamente aceptable del mismo. 2.- El compuesto de conformidad con la reivindicación 1, caracterizado porque R5 representa alquilo de C1-C5 sustituido por cicloalquilo de C3-C10 sustituido o no sustituido o por arilo sustituido o no sustituido; o representa arilo sustituido o no sustituido, o sal farmacéuticamente aceptable del mismo. 3.- El compuesto de conformidad con la reivindicación 2, caracterizado porque R5 representa alquilo de C1-C5 sustituido por cicloalquilo de C3-C10 que es no sustituido o sustituido por uno o más sustituyentes seleccionados del grupo que consiste de alquilo de C1-C5, hidroxi, alcoxi de C1-C5 y halógeno, o por arilo que es no sustituido o sustituido por uno o más sustituyentes seleccionados del grupo que consiste de alquilo de C1-C5, hidroxi, alcoxi de C1-C5 y halógeno; o representa arilo que es no sustituido o sustituido por uno o más sustituyentes seleccionados del grupo que consiste de alquilo de C1-C5, hidroxi, alcoxi de C1-C5 y halógeno, o sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060073029 | 2006-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6160228A2 true CO6160228A2 (es) | 2010-05-20 |
Family
ID=38997391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09009364A CO6160228A2 (es) | 2006-08-02 | 2009-02-02 | Inhibidores de caspasa basados en la estructura de piridazinona |
Country Status (13)
Country | Link |
---|---|
US (1) | US8481537B2 (es) |
EP (1) | EP2046757A4 (es) |
JP (1) | JP5102834B2 (es) |
KR (1) | KR20080012176A (es) |
CN (1) | CN101506174B (es) |
AU (1) | AU2007279550B2 (es) |
BR (1) | BRPI0715462A2 (es) |
CA (1) | CA2659084C (es) |
CO (1) | CO6160228A2 (es) |
EA (1) | EA015886B1 (es) |
MX (1) | MX2009001155A (es) |
NZ (1) | NZ574791A (es) |
WO (1) | WO2008016239A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
JP2012131708A (ja) * | 2009-04-28 | 2012-07-12 | Nissan Chem Ind Ltd | 4位置換ピリダジノン化合物及びp2x7受容体阻害剤 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2932484A1 (en) | 2013-12-05 | 2015-06-11 | Bayer Cropscience Aktiengesellschaft | N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives |
WO2015082587A1 (en) | 2013-12-05 | 2015-06-11 | Bayer Cropscience Ag | N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives |
EP3126362B1 (en) | 2014-04-02 | 2022-01-12 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2016023877A1 (en) * | 2014-08-14 | 2016-02-18 | F. Hoffmann-La Roche Ag | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
CN108997155A (zh) * | 2018-09-17 | 2018-12-14 | 吉尔生化(上海)有限公司 | 一种多肽原料天冬氨酸β-叔丁酯α-甲酯盐酸盐的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163214A1 (en) * | 1999-03-16 | 2001-12-19 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
WO2002094263A2 (en) * | 2001-05-23 | 2002-11-28 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
US20060069038A1 (en) * | 2003-02-07 | 2006-03-30 | John Colucci | Irreversible caspase-3 inhibitors as active site probes |
PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
-
2007
- 2007-07-27 WO PCT/KR2007/003617 patent/WO2008016239A1/en active Application Filing
- 2007-07-27 CN CN2007800315495A patent/CN101506174B/zh not_active Expired - Fee Related
- 2007-07-27 JP JP2009522711A patent/JP5102834B2/ja not_active Expired - Fee Related
- 2007-07-27 AU AU2007279550A patent/AU2007279550B2/en not_active Ceased
- 2007-07-27 BR BRPI0715462-3A patent/BRPI0715462A2/pt not_active IP Right Cessation
- 2007-07-27 NZ NZ574791A patent/NZ574791A/en not_active IP Right Cessation
- 2007-07-27 US US12/375,890 patent/US8481537B2/en not_active Expired - Fee Related
- 2007-07-27 KR KR1020070075737A patent/KR20080012176A/ko not_active Application Discontinuation
- 2007-07-27 EP EP07793275A patent/EP2046757A4/en not_active Withdrawn
- 2007-07-27 CA CA2659084A patent/CA2659084C/en not_active Expired - Fee Related
- 2007-07-27 MX MX2009001155A patent/MX2009001155A/es active IP Right Grant
- 2007-07-27 EA EA200970164A patent/EA015886B1/ru not_active IP Right Cessation
-
2009
- 2009-02-02 CO CO09009364A patent/CO6160228A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA015886B1 (ru) | 2011-12-30 |
AU2007279550B2 (en) | 2012-08-09 |
EP2046757A4 (en) | 2011-04-27 |
CN101506174A (zh) | 2009-08-12 |
MX2009001155A (es) | 2009-02-10 |
NZ574791A (en) | 2011-12-22 |
JP5102834B2 (ja) | 2012-12-19 |
BRPI0715462A2 (pt) | 2014-05-06 |
AU2007279550A1 (en) | 2008-02-07 |
US8481537B2 (en) | 2013-07-09 |
EP2046757A1 (en) | 2009-04-15 |
WO2008016239A1 (en) | 2008-02-07 |
CA2659084A1 (en) | 2008-02-07 |
EA200970164A1 (ru) | 2009-08-28 |
CA2659084C (en) | 2011-07-12 |
JP2009545585A (ja) | 2009-12-24 |
US20090291959A1 (en) | 2009-11-26 |
KR20080012176A (ko) | 2008-02-11 |
CN101506174B (zh) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160228A2 (es) | Inhibidores de caspasa basados en la estructura de piridazinona | |
AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
CR9961A (es) | Derivados de espiro aza-sustituidos | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
UY30105A1 (es) | Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas. | |
AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
CO6280485A2 (es) | Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina | |
CO6241190A2 (es) | Compuestos para inhibicion enzimatica | |
AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
UY29702A1 (es) | Inhibidores macrocíclicos del virus de hepatitis c | |
AR033620A1 (es) | Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
CO6341610A2 (es) | Compuesto heterociclilo aromatico que contiene nitrogeno. | |
CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
CO6241123A2 (es) | Moduladores de la gamma secretasa | |
AR053149A1 (es) | Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas |